The Food and Drug Administration (FDA) has just released a Q&A formatted guidance about charging for investigational drugs under an IND. While the guidance is geared toward industry, it contains helpful information for investigators who sponsor their own INDs, and for study teams and HRPP staff involved in drafting consent forms and creating budgets. We recommend keeping this guidance handy as a reference when working on IND studies.